Inanc, N. Et Al. 2018. IS THERE ANY DIFFERENCE IN RA PATIENTS FOR METHOTREXATE USE VS. LEFLUNOMIDE USE AS A CONCOMITANT TREATMENT WITH BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN TURKBIO REGISTRY?. Congress of the European-League-Against-Rheumatism (EULAR) , (Amsterdam, Netherlands), 611-612.

Inanc, N., Ozen, G., Yalcinkaya, Y., Dalkilic, E., Koca, S. S., Can, G., ... Karatas, A.(2018). IS THERE ANY DIFFERENCE IN RA PATIENTS FOR METHOTREXATE USE VS. LEFLUNOMIDE USE AS A CONCOMITANT TREATMENT WITH BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN TURKBIO REGISTRY? . Congress of the European-League-Against-Rheumatism (EULAR) (pp.611-612). Amsterdam, Netherlands

Inanc, N. Et Al. "IS THERE ANY DIFFERENCE IN RA PATIENTS FOR METHOTREXATE USE VS. LEFLUNOMIDE USE AS A CONCOMITANT TREATMENT WITH BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN TURKBIO REGISTRY?," Congress of the European-League-Against-Rheumatism (EULAR), Amsterdam, Netherlands, 2018

Inanc, N. Et Al. "IS THERE ANY DIFFERENCE IN RA PATIENTS FOR METHOTREXATE USE VS. LEFLUNOMIDE USE AS A CONCOMITANT TREATMENT WITH BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN TURKBIO REGISTRY?." Congress of the European-League-Against-Rheumatism (EULAR) , Amsterdam, Netherlands, pp.611-612, 2018

Inanc, N. Et Al. (2018) . "IS THERE ANY DIFFERENCE IN RA PATIENTS FOR METHOTREXATE USE VS. LEFLUNOMIDE USE AS A CONCOMITANT TREATMENT WITH BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN TURKBIO REGISTRY?." Congress of the European-League-Against-Rheumatism (EULAR) , Amsterdam, Netherlands, pp.611-612.

@conferencepaper{conferencepaper, author={N. Inanc Et Al. }, title={IS THERE ANY DIFFERENCE IN RA PATIENTS FOR METHOTREXATE USE VS. LEFLUNOMIDE USE AS A CONCOMITANT TREATMENT WITH BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN TURKBIO REGISTRY?}, congress name={Congress of the European-League-Against-Rheumatism (EULAR)}, city={Amsterdam}, country={Netherlands}, year={2018}, pages={611-612} }